Cyclacel hosting research & development day

-program update on its cdk2/9 inhibitor, oral fadraciclib, and oral plk1 inhibitor, cyc140, for the treatment of advanced solid tumors and lymphoma-
CYCC Ratings Summary
CYCC Quant Ranking